Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...
Avidity Biosciences (RNA) announced positive del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular ...
GlobalData on MSN5d
Avidity’s del-zota elicits 25% increase in dystrophin in DMD patientsThe company plans to submit a biologics licence application to the US Food and Drug Administration later this year.
Results from the company’s Explore44 trial (NCT05670730) found that targeted delivery of del-zota, an antibody oligonucleotide conjugate (AOC), saw an approximate increase of 40% in exon 44 ...
After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based ...
The EXPLORE44 study enrolled DMD patients with DMD mutations amenable to exon 44 skipping (DMD44), a group that accounts for around 6% of all DMD cases in the US. It showed a statistically ...
Avidity Biosciences, Inc. announced positive results from their phase 1/2 EXPLORE44 trial of del-zota in 23 patients living with Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44), ...
The results from the phase 1/2 EXPLORE44 clinical trial (NCT05670730) were the first in-patient experiences with AOC 1044. The randomized, placebo-controlled, double-blind study assessed the safety, ...
SAN DIEGO - Avidity Biosciences, Inc. (NASDAQ:RNA), a biotechnology company with a market capitalization of $3.74 billion, has announced positive topline data from its Phase 1/2 EXPLORE44 trial for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback